xoma (1 Viewer)
- Creatore Discussione osinod
- Data di Inizio
osinod
Banned
ndex- P/E- EPS (ttm)0.00 Insider Own0.23% Shs Outstand261.19M Perf Week1.93% Market Cap151.75M Forward P/E- EPS next Y-0.18 Insider Trans- Shs Float260.59M Perf Month13.92% Income0.55M PEG- EPS next Q-0.05 Inst Own14.56% Short Float0.74% Perf Quarter-15.80% Sales98.43M P/S1.54 EPS this Y100.95% Inst Trans29.84% Short Ratio0.43 Perf Half Y-28.27% Book/sh0.08 P/B7.26 EPS next Y50.00% ROA0.92% Target Price1.98 Perf Year9.62% Cash/sh0.09 P/C6.35 EPS next 5Y- ROE- 52W Range0.40 - 1.34 Perf YTD-17.00% Dividend- P/FCF21.16 EPS past 5Y0.00% ROI1.48% 52W High-56.64% Beta1.72 Dividend %- Quick Ratio1.72 Sales past 5Y93.11% Gross Margin- 52W Low45.25% ATR0.03 Employees335 Current Ratio1.72 Sales Q/Q-41.50% Oper. Margin9.46% RSI (14)60.57 Volatility5.30% 5.93% OptionableNo Debt/Eq0.76 EPS Q/Q-79.75% Profit Margin0.56% Rel Volume0.28 Prev Close0.57 ShortableYes LT Debt/Eq0.76 EarningsMar 08 Payout0.00% Avg Volume4.44M Price0.58 Recom1.50 SMA204.78% SMA509.13% SMA200-19.64% Volume1,243,436 Change1.93%
osinod
Banned
XOMA Ltd. has announced results that demonstrate its monoclonal antibody technology XOMA 3AB's ability to neutralize botulinum neurotoxin Type A, a bioterror threat that causes paralysis.
One single antibody is often not effective in neutralizing a botulism as well as many other infectious diseases, especially in cases where multiple strains or subtypes exist. XOMA's technology combats this by co-formulating and delivering multiple antibodies in a single injectable solution, potentially increasing efficacy for infectious and other diseases.
XOMA 3AB consists of three human antibodies that bind to unique epitopes on the botulinum A toxin. In composite, the antibodies have shown to have unprecedented potency against the toxin. XOMA 3AB is being developed under existing research contracts with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
"These results highlight the breadth of XOMA's advanced expertise in antibody development, optimization and formulation," Patrick J. Scannon, M.D., Ph.D., and executive vice president and chief medical officer of Xoma, said. "We are utilizing multiple technologies to provide stable products with longer shelf lives and lower costs than third generation biologics. For the first time, we have also solved a key quality problem in ensuring the mix and potency of multiple antibodies. Specialized assays were developed and implemented to ensure precise characterization, stability and release of this multiple antibody cocktail."
One single antibody is often not effective in neutralizing a botulism as well as many other infectious diseases, especially in cases where multiple strains or subtypes exist. XOMA's technology combats this by co-formulating and delivering multiple antibodies in a single injectable solution, potentially increasing efficacy for infectious and other diseases.
XOMA 3AB consists of three human antibodies that bind to unique epitopes on the botulinum A toxin. In composite, the antibodies have shown to have unprecedented potency against the toxin. XOMA 3AB is being developed under existing research contracts with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
"These results highlight the breadth of XOMA's advanced expertise in antibody development, optimization and formulation," Patrick J. Scannon, M.D., Ph.D., and executive vice president and chief medical officer of Xoma, said. "We are utilizing multiple technologies to provide stable products with longer shelf lives and lower costs than third generation biologics. For the first time, we have also solved a key quality problem in ensuring the mix and potency of multiple antibodies. Specialized assays were developed and implemented to ensure precise characterization, stability and release of this multiple antibody cocktail."
osinod
Banned
31 marzo
VICL/ Phase II data/ 1H 2010 VIAP/ Phase II Results expected CPEX- Phase 2a Results OGXI to begin Phase III trials in 2010 GTXI - Clinical Trials INFI - Clinical Trials ACHN/ Phase I results/ 1Q10 XOMA- Clinical Trials KERX - Clinical Trials SVNT- BLA Resubmission ALNY- 2010 Pipeline goals ANDS- Phase II data
VICL/ Phase II data/ 1H 2010 VIAP/ Phase II Results expected CPEX- Phase 2a Results OGXI to begin Phase III trials in 2010 GTXI - Clinical Trials INFI - Clinical Trials ACHN/ Phase I results/ 1Q10 XOMA- Clinical Trials KERX - Clinical Trials SVNT- BLA Resubmission ALNY- 2010 Pipeline goals ANDS- Phase II data
osinod
Banned
XOMA LTD. : WHY IT COST $0.60 WHEN IT'S WORTH $8 ? 3 comments
Mar 27, 2010 09:23 AM | about stocks: XOMA, AMGN, NVS, NOVN, BVT, REGN, EBS, PFE, AVII, ASTM, ARRY, CYTR, HEB, INSM, NYMX, PPHM, PARD, TRMS, UGNE, UGNE.OB, YMI, AEZS, FBT, BBH, PBE, PBTQ, XBI, PPH, PJP, XPH, IHE, DNA, UCBJF.PK, TKPHF.PK, TKPHY.PK, SGP, BAYRY.PK, BYERF.PK
You know XOMA and can read about it on their website, I will only highlight few things worth noticing, here they are.
Dust free balance sheet if you look forward, not back (no significant debt, 5 year revenue growth 100%, losses EPS attributed to R&D not bad management and in biotech field the losses very often turn into gold eggs because you need to lose first investing in pipeline so later to enjoy the golden crop, when sales start to grow then it's in hundreds % like in 2005 by 500% or 2007 by 200%, when sales disappoint investors instead of buying this full basket of platinum eggs, run for cover like XOMA is suddenly their enemy and they've forgot a brilliant track record. Also they are always one step away from attack by bigger competitor and $0.60 stock is a real cake for which they waited almost 10 years. Such deal is very, very likely now more than ever but the premium buyer will have to pay is a big question because insiders know how much their stock is worth to them. I think XOMA first will go to $8 and only then it will be acquired because investment banks M&A junkies push for higher priced deals where commissions are bigger and competitors more often value (afraid) a jumbo cap than micro cap.
Notice collaboration with bigger pharma and biotech companies who need XOMA more than XOMA needs them, example Kaketsuken; National Institute of Allergy and Infectious Diseases; SRI International; Genentech, Inc.; UCB Celltech; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited and more is on the way. A BUY BUY.
Below I will show you how to buy XOMA risk free, as you see on a chart XOMA doesn't have any correlation to biotechnology sector as a whole on the opposite, it's beta correlation with BBH is - (minus) 1. It means that when most big cap biotech stocks will go down XOMA will shock most bearish investors and fly for no reason (with the same balance sheet, same news) because hedge funds will buy XOMA stock as it offers safety in the declining market more than other stocks in this sector.
Also Capital IQ shows that XOMA's Beta is 1.62 but this is wrong, it's beta correlation with S&P 500 is at minus - 8 based on CIFRA model. It means that XOMA can go up 80% for example if S&P 500 to go down 10%. Please don't forget that Beta is theoretical number only, it's not perfect.
So you can sell short $100,000 in BBH and buy $100,000 XOMA risk free.
And let me know after 1 year how much money you have made.
link :
http://seekingalpha.com/instablog/5...7-xoma-ltd-why-it-cost-0-60-when-it-s-worth-8
Mar 27, 2010 09:23 AM | about stocks: XOMA, AMGN, NVS, NOVN, BVT, REGN, EBS, PFE, AVII, ASTM, ARRY, CYTR, HEB, INSM, NYMX, PPHM, PARD, TRMS, UGNE, UGNE.OB, YMI, AEZS, FBT, BBH, PBE, PBTQ, XBI, PPH, PJP, XPH, IHE, DNA, UCBJF.PK, TKPHF.PK, TKPHY.PK, SGP, BAYRY.PK, BYERF.PK
- Font:
- Recommend
2
Share this page
Share0
You know XOMA and can read about it on their website, I will only highlight few things worth noticing, here they are.
Dust free balance sheet if you look forward, not back (no significant debt, 5 year revenue growth 100%, losses EPS attributed to R&D not bad management and in biotech field the losses very often turn into gold eggs because you need to lose first investing in pipeline so later to enjoy the golden crop, when sales start to grow then it's in hundreds % like in 2005 by 500% or 2007 by 200%, when sales disappoint investors instead of buying this full basket of platinum eggs, run for cover like XOMA is suddenly their enemy and they've forgot a brilliant track record. Also they are always one step away from attack by bigger competitor and $0.60 stock is a real cake for which they waited almost 10 years. Such deal is very, very likely now more than ever but the premium buyer will have to pay is a big question because insiders know how much their stock is worth to them. I think XOMA first will go to $8 and only then it will be acquired because investment banks M&A junkies push for higher priced deals where commissions are bigger and competitors more often value (afraid) a jumbo cap than micro cap.
Notice collaboration with bigger pharma and biotech companies who need XOMA more than XOMA needs them, example Kaketsuken; National Institute of Allergy and Infectious Diseases; SRI International; Genentech, Inc.; UCB Celltech; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited and more is on the way. A BUY BUY.
Below I will show you how to buy XOMA risk free, as you see on a chart XOMA doesn't have any correlation to biotechnology sector as a whole on the opposite, it's beta correlation with BBH is - (minus) 1. It means that when most big cap biotech stocks will go down XOMA will shock most bearish investors and fly for no reason (with the same balance sheet, same news) because hedge funds will buy XOMA stock as it offers safety in the declining market more than other stocks in this sector.
Also Capital IQ shows that XOMA's Beta is 1.62 but this is wrong, it's beta correlation with S&P 500 is at minus - 8 based on CIFRA model. It means that XOMA can go up 80% for example if S&P 500 to go down 10%. Please don't forget that Beta is theoretical number only, it's not perfect.
So you can sell short $100,000 in BBH and buy $100,000 XOMA risk free.
And let me know after 1 year how much money you have made.
link :
http://seekingalpha.com/instablog/5...7-xoma-ltd-why-it-cost-0-60-when-it-s-worth-8
Madeye
Nuovo forumer
Ciao osinod,
ti segnalo anche la mia piccola analisi su Xoma, che gode di ottimi fondamentali..Giants of Finance: Analisi: Xoma
ti segnalo anche la mia piccola analisi su Xoma, che gode di ottimi fondamentali..Giants of Finance: Analisi: Xoma
Madeye
Nuovo forumer
Al premarket quota già .80, grazie all'annuncio di due nuovi brevetti. Questa è la news: XOMA Issued Two New U.S. Patents for Methods of Treating Type 2 Diabetes and Inflammatory Diseases Using Interleukin-1 Beta Antibodies - Yahoo! Finance
osinod
Banned
bene bene Madeye stiamo mettendo su' una squadra alla grande su' questo forum
in fondo è il mio scopo da soli non si crea nulla di importante
è gia' quasi un + 50%, ma gli obbiettivi chiaramente sono molto piu' ambiziosi piu' tardi vedro' di aggiungerci piu' grafici per vedere meglio questo ottimo momento
